[1. TABRINZIA-TABRIZI S., GHOLAMPOUR M., MANSOURITORGHABEH H. A close insight to factor VIII inhibitor in the congenital hemophilia A. Expert Rev Hematol. 2016; 9:903-913.10.1080/17474086.2016.120855427367203]Search in Google Scholar
[2. RODRIGUEZ-MERCHÁN E.C. Orthopedic surgery is possible in hemophilic patients with inhibitors. Am J Orthop (Belle Mead NJ). 2012; 41:570-574.]Search in Google Scholar
[3. FINN J.D., OZELO M.C., SABATINO D.E., FRANCK H.W., MERRICKS E.P., CRUDELE J.M., et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood. 2010; 116:5842-5848.10.1182/blood-2010-06-288001303138020876851]Search in Google Scholar
[4. LAI J., HOUGH C., TARRANT J., LILLICRAP D. Biological considerations of plasma-derived and recombinant factor VIII immunogenicity. Blood. 2017; 129:3147-3154.10.1182/blood-2016-11-75088528432221]Search in Google Scholar
[5. OWAIDAH T., MOMEN A.A., ALZAHRANI H., ALMUSA A., ALKASIM F., TARAWAH A., et al. The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program. Medicine (Baltimore). 2017; 96:e5456.10.1097/MD.0000000000005456526615028079788]Search in Google Scholar
[6. BENSON G., AUERSWALD G., ELEZOVIĆ I., LAMBERT T., LJUNG R., MORFINI M., et al. Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice. Eur J Haematol. 2012; 88:371-379.10.1111/j.1600-0609.2012.01754.x22260405]Search in Google Scholar
[7. ROCINO A., FRANCHINI M., COPPOLA A. Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX. J Clin Med. 2017; 6;pii:E46.10.3390/jcm6040046540677828420167]Search in Google Scholar
[8. ECKHARDT C.L., LOOMANS J.I., VAN VELZEN A.S., PETERS M., MAUSER-BUNSHOTEN E.P., SCHWAAB R., et al. Inhibitor development and mortality in non-severe hemophilia A. J Thromb Haemost. 2015; 13:1217-1225.10.1111/jth.1299025912309]Search in Google Scholar
[9. FRANCHINI M., LIPPI G. Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future? Thromb Res. 2016; 148:96-100.10.1016/j.thromres.2016.10.024]Search in Google Scholar
[10. VAN DEN BERG H.M., HASHEMI S.M., FISCHER K., PETRINI P., LJUNG R., RAFOWICZ A., et al. Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors. Thromb Haemost. 2016; 115:729-737.10.1160/TH15-08-069226632988]Search in Google Scholar
[11. VAN DEN BERG H.M., LJUNG R.; PEDNET STUDY GROUP. Can a “center effect” explain the higher frequency of inhibitors for a second-generation recombinant factor VIII product? Blood. 2015; 126:2164-2165.10.1182/blood-2015-08-663583]Search in Google Scholar
[12. FISCHER K., IORIO A., LASSILA R., PEYVANDI F., CALIZZANI G., GATT A., et al. Inhibitor development in non-severe haemophilia across Europe. Thromb Haemost. 2015; 114:670-675.10.1160/TH14-12-104426293381]Search in Google Scholar
[13. KARAMAN K, AKBAYRAM S, GARIPARDIÇ M, ÖNER AF. Diagnostic evaluation of our patients with hemophilia A: 17-year experience. Turk Pediatri Ars. 2015; 50:96-101.10.5152/tpa.2015.2516452399226265893]Search in Google Scholar
[14. BLATNY J., KOMRSKA V., BLAZEK B., PENKA M., OVESNA P.; CZECH NATIONAL HAEMOPHILIA PROGRAMME. Inhibitors incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 2003. Blood Coagul Fibrinolysis. 2015; 26:673-678.10.1097/MBC.000000000000029825886834]Search in Google Scholar
[15. HALIMEH S., BIDLINGMAIER C., HELLER C., GUTSCHE S., HOLZHAUER S., KENET G., et al. Risk factors for high-titer inhibitor development in children with hemophilia A: results of a cohort study. Biomed Res Int. 2013; 2013:901975.10.1155/2013/901975380755924199202]Search in Google Scholar
[16. TUNSTALL O., ASTERMARK J. Strategies for reducing inhibitor formation in severe haemophilia. Eur J Haematol. 2015; 94 Suppl 77:45-50.10.1111/ejh.1250125560794]Search in Google Scholar
[17. ÁLVAREZ T., SOTO I., ASTERMARK J. Non-genetic risk factors and their influence on the management of patients in the clinic. Eur J Haematol. 2015; 94 Suppl 77:2-6.10.1111/ejh.1249425560787]Search in Google Scholar
[18. CARACO M., RE W., EWENSTEIN B. The role of previously untreated patient studies in understanding the development of FVIII inhibitors. Haemophilia. 2016; 22:22-31.10.1111/hae.1279026315604]Search in Google Scholar
[19. TER AVEST P.C., FISCHER K., MANCUSO M.E., SANTAGOSTINO E., YUSTE V.J., VAN DEN BERG H.M., et al. Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. J Thromb Haemost. 2008; 6:2048-2054.10.1111/j.1538-7836.2008.03187.x18983511]Search in Google Scholar
[20. MARCUCCI M., MANCUSO M.E., SANTAGOSTINO E., KENET G., ELALFY M., HOLZHAUER S., et al. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis. Thromb Haemost. 2015; 113:958-967.10.1160/TH14-07-062125631402]Search in Google Scholar
[21. KURNIK K., BIDLINGMAIER C., ENGL W., CHEHADEH H., REIPERT B., AUERSWALD G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia. 2010; 16:256-262.10.1111/j.1365-2516.2009.02122.x19878331]Search in Google Scholar
[22. JAMES E.A., VAN HAREN S.D., ETTINGER R.A., FIJNVANDRAAT K., LIBERMAN J.A., KWOK W.W., et al. T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site. J Thromb Haemost. 2011; 9:689-699.10.1111/j.1538-7836.2011.04202.x432317821251204]Search in Google Scholar
[23. YADA K., NOGAMI K., TAKEYAMA M., OGIWARA K., WAKABAYASHI H., SHIMA M. Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity. J Thromb Haemost. 2015; 13:1843-1853.10.1111/jth.1311826278069]Search in Google Scholar
[24. SHIMA M., LILLICRAP D., KRUSE-JARRES R. Alternative therapies for the management of inhibitors. Haemophilia. 2016; 22 Suppl 5:36-41.10.1111/hae.1300527405674]Search in Google Scholar
[25. LAI J.D., MOOREHEAD P.C., SPONAGLE K., STEINITZ K.N., REIPERT B.M., HOUGH C, et al. Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A. Blood. 2016; 127:3439-3449.10.1182/blood-2015-11-67928227034428]Search in Google Scholar
[26. LÖVGREN K.M., SØNDERGAARD H., SKOV S., WIINBERG B. Joint bleeds increase the inhibitor response to human factor VIII in a rat model of severe haemophilia A. Haemophilia 2016; 22:772-779.10.1111/hae.1301427439658]Search in Google Scholar
[27. FISCHER K., LASSILA R., PEYVANDI F., CALIZZANI G., GATT A., LAMBERT T., et al. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost. 2015; 113:968-975.10.1160/TH14-10-082625567324]Search in Google Scholar
[28. MANCUSO M.E., MANNUCCI P.M., ROCINO A., GARAGIOLA I., TAGLIAFERRI A., SANTAGOSTINO E. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A. J Thromb Haemost. 2012; 10:781-790.10.1111/j.1538-7836.2012.04691.x22452823]Search in Google Scholar
[29. FEISTRITZER C., SCHMIDT S. Reversal of direct oral anticoagulants in hemophilia treatment: ASH meeting 2015. Memo. 2016; 9:131-135.10.1007/s12254-016-0284-2504548327752290]Search in Google Scholar
[30. MATHEW P., DINTER H., CHURCH N., HUMPHRIES T.J., KULKARNI R. Inhibitors in haemophilia A: a perspective on clotting factor products as a potential contributing factor. Haemophilia. 2016; 22:334-341.10.1111/hae.1288826843214]Search in Google Scholar
[31. CALVEZ T., CHAMBOST H., CLAEYSSENS-DONADEL S., D’OIRON R., GOULET V., GUILLET B., et al. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood. 2014; 124:3398-3408.10.1182/blood-2014-07-58634725253771]Search in Google Scholar
[32. COLLINS P.W., PALMER B.P., CHALMERS E.A., HART D.P., LIESNER R., RANGARAJAN S., et al. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood. 2014; 124:3389-3397.10.1182/blood-2014-07-580498424603725339360]Search in Google Scholar
[33. AZNAR J.A., MORET A., IBÁÑEZ F., VILA C., CABRERA N., MESA E., et al. Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A. Haemophilia. 2014; 20:624-629.10.1111/hae.1243924697977]Search in Google Scholar
[34. KOCHER S., ASMELASH G., MAKKI V., MÜLLER S., KREKELER S., ALESCI S., et al. Inhibitor development after changing FVIII/IX products in patients with haemophilia. Hamostaseologie. 2012; 32 Suppl 1:S39-42.10.1055/s-0037-1619773]Search in Google Scholar
[35. PARRA LOPEZ R., NEMES L., JIMENEZ-YUSTE V., RUSEN L., CID A.R., CHARNIGO R.J., et al. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings. Thromb Haemost. 2015; 114:676-684.10.1160/TH14-09-076026293201]Search in Google Scholar
[36. MANNUCCI P.M., MANCUSO M.E., FRANCHINI M. Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A. J Thromb Haemost. 2016; 14:1330-1336.10.1111/jth.1335627155314]Search in Google Scholar
[37. KAHLE J., ORLOWSKI A., STICHEL D., HEALEY J.F., PARKER E.T., JAKEMIN M., et al. Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A. Blood. 2017; pii:blood-2016-11-751347.10.1182/blood-2016-11-751347555357328507083]Search in Google Scholar
[38. MATINO D., GARGARO M., SANTAGOSTINO E., DI MINNO M.N., CASTAMAN G., MORFINI M., et al. IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. J Clin Invest. 2015; 125:3766-3781.10.1172/JCI81859460712126426076]Search in Google Scholar
[39. OLDENBURG J., LACROIX-DESMAZES S., LILLICRAP D. Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity. Haematologica. 2015; 100:149-156.10.3324/haematol.2014.112821480314725638804]Search in Google Scholar
[40. MILLER L., WEISSMÜLLER S., RINGLER E., CRAUWELS P., van ZANDBERGEN G., SEITZ R., et al. Danger signal-dependent activation of human dendritic cells by plasma-derived factor VIII products. Thromb Haemost. 2015; 114:268-276.10.1160/TH14-09-078925947149]Search in Google Scholar
[41. JACQUEMIN M., SAINT-REMY J.M. T cell response to FVIII. Cell Immunol. 2016; 301:8-11.10.1016/j.cellimm.2015.09.00726435345]Search in Google Scholar
[42. WANG X., SU J., SHERMAN A., ROGERS G.L., LIAO G., HOFFMAN B.E., et al. Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells. Blood. 2015; 125:2418-2427.10.1182/blood-2014-08-597070439201025700434]Search in Google Scholar
[43. ALLACHER P., BAUMGARTNER C.K., PORDES A.G., AHMAD R.U., SCHWARZ H.P., REIPERT B.M. Stimulation and inhibition of FVIII-specific memory B-cell responses by CpG-B (ODN 1826), a ligand for Toll-like receptor 9. Blood. 2011; 117:259-267.10.1182/blood-2010-06-28900920889922]Search in Google Scholar
[44. WERWITZKE S., VOLLACK N., VON HORNUNG M., KALIPPKE K., KUTZSCHBACH J., TRUMMER A., et al. Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro. Thromb Haemost. 2015; 114:1127-1135.10.1160/TH14-06-053526245154]Search in Google Scholar
[45. BATOROVA A., JANKOVICOVA D., MORONGOVA A., BUBANSKA E., PRIGANCOVA T., HORAKOVA J., et al. Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia. Semin Thromb Hemost. 2016; 42:550-562.10.1055/s-0036-158110727235830]Search in Google Scholar
[46. MANNUCCI P.M., GARAGIOLA I. Factor VIII products in haemophilia A: one size fits all? Thromb Haemost 2015; 113:911-914.10.1160/TH15-04-0273]Search in Google Scholar
[47. DASGUPTA S., REPESSE Y., BAYRY J., NAVARRETE A.M., WOOTLA B., DELIGNAT S., et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood. 2007; 109:610–612.10.1182/blood-2006-05-02275616985172]Search in Google Scholar
[48. QADURA M., WATERS B., BURNETT E., CHEGENI R., BRADSHAW S., HOUGH C., et al. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in haemophilia A mice. Blood. 2009; 114:871-880.10.1182/blood-2008-09-17464919411636]Search in Google Scholar
[49. GHIO M., CONTINI P., OTTONELLO L., ARDUINO N., GRINGERI A., INDIVERI F., et al. Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro. Thromb Haemost. 2003; 89:365–373.10.1055/s-0037-1613454]Search in Google Scholar
[50. PEYVANDI F., MANNUCCI P.M., GARAGIOLA I., EL-BESHLAWY A., ELALFY M., RAMANAN V., et al. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016; 374:2054-2064.10.1056/NEJMoa151643727223147]Search in Google Scholar
[51. MANNUCCI P.M., MANCUSO M.E., SANTAGOSTINO E. How we choose factor VIII to treat haemophilia. Blood. 2012; 119:4108-4114.10.1182/blood-2012-01-39441122411872]Search in Google Scholar
[52. PEYVANDI F., MANNUCCI P.M., PALLA R., ROSENDAAL F.R. SIPPET: methodology, analysis and generalizability. Haemophilia. 2017; 23:353-361.10.1111/hae.1320328306186]Search in Google Scholar
[53. AFONJA O., KOZAK R., PETRARO P., MICHAELS L.A., MATHEW P., LEMM G., et al. Baby hamster kidney cell-derived recombinant factor VIII: a quarter century of learning and clinical experience. Expert Rev Hematol. 2016; 9:1151-1164.10.1080/17474086.2017.125955927841041]Search in Google Scholar
[54. HARTMANN J., CROTEAU S.E. 2017 Clinical trials update: Innovations in hemophilia therapy. Am J Hematol. 2016; 91:1252-1260.10.1002/ajh.2454327563744]Search in Google Scholar
[55. YOON J., SCHMIDT A., ZHANG A.H., KÖNIGS C., KIM Y.C., SCOTT D.W. FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII. Blood. 2017; 129:238-245.10.1182/blood-2016-07-727834523421928064157]Search in Google Scholar